Search results for "Combined"

showing 10 items of 1205 documents

Future perspectives in hepatocellular carcinoma.

2010

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefits have been available in up to 70% of patients. However, major progress has been achieved with regard to surveillance, early diagnosis, and multimodal treatment approaches during the last years leading to an improvement in prognosis. Particularly, the increasing knowledge of molecular hepatocarcinogenesis today provides the opportunity for targeted therapy. The multikinase inhibitor sorafenib has broadened the therapeutic horizon for patients with advanced disease and is current…

SorafenibOncologyAblation Techniquesmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyTargeted therapyInternal medicinemedicineAdjuvant therapyCombined Modality TherapyHumansChemoembolization TherapeuticPrecision MedicineTranscatheter arterial chemoembolizationProtein Kinase InhibitorsHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality TherapyFibrosisLiver TransplantationHepatocellular carcinomaPersonalized medicinebusinessmedicine.drugForecastingDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

2015

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70–85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. Th…

SorafenibOncologyCancer Researchmedicine.medical_specialtyrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentliving donorLiver transplantationMilan criteriaGastroenterologyLeukocyte CountRisk FactorsInternal medicinemedicineBiomarkers TumorCombined Modality TherapyHumansalpha-FetoproteinPerioperative PeriodSurvival rateimmunosuppressionbusiness.industryRisk FactorLiver NeoplasmsImmunosuppressionGeneral MedicinePerioperativehepatocellular carcinomamedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationTumor BurdenOncologyLiver NeoplasmHepatocellular carcinomaalpha-FetoproteinsNeoplasm Recurrence Localbusinessmedicine.drugHumanFuture oncology (London, England)
researchProduct

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

2015

According to the guidelines of the European Association for the Study of the Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in five stages (0, A, B, C and D) on the basis of a number of prognostic and treatment- related variables such as tumor status and liver function. A specific treat ment approach is then proposed for each of the above-mentioned stages. Transarterial chemoembolization (TACE) is recommended as first-line therapy in the treatment of patients with intermediate-stage (BCLC-B class) HCC [1]. The efficacy of this procedure…

SorafenibOncologyNiacinamideCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyHCC; TACE; combination therapy; intermediate stage; sorafenibAntineoplastic Agentscombination therapyInternal medicineMedicineHumansStage (cooking)Chemoembolization TherapeuticHCCProtein Kinase InhibitorsTACEintermediate stagePerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsGeneral Medicinemedicine.diseaseCombined Modality Therapydigestive system diseasesPortal vein thrombosisSurgeryOncologyHepatocellular carcinomasorafenibLiver functionbusinessLiver cancermedicine.drug
researchProduct

A macroeconomic analysis of the public investments in European combined transport

2009

Intermodal transport has been recognized as a priority by the European Union, that has defined different budget allocations of investments to improve the shifting from road to intermodal transport, which is more sustainable. In this context, the main aim of the paper is to discuss the macroeconomic effects, in terms of economic growth, welfare and trade, of these public investments for combined transport, which aspects have been neglected in literature. A multi-country computable general equilibrium model has been used. The main results have been that the European Union benefits from these investments, but at international level, USA and Japan would lose in terms of welfare. Furthermore, th…

Statistics and ProbabilityMacroeconomicsComputable general equilibriumInternational levelEconomics and Econometricsmedia_common.quotation_subjectContext (language use)International economicsComputable general equilibrium model public investments combined transport sensitivity analysisMathematics (miscellaneous)Exchange rateSettore SECS-P/03 - Scienza Delle FinanzeEconomicsmedia_common.cataloged_instanceAllocative efficiencyEuropean unionRobustness (economics)WelfareSocial Sciences (miscellaneous)media_common
researchProduct

Surgical treatment of solitary sternal metastasis from breast cancer Case report

2016

Bone metastasis is a frequent and early complication of breast cancer. This case report describes a technique for a partial exeresis of the sternum and the reconstruction of the pleura with autologous dermis from the lower abdomen and the loss of substance with a myocutaneous flap.We describe the case of a 50-year old woman with a sternal excavated lesion with pathologic fracture due to an invasive adenocarcinoma, treated with a partial exeresis of the sternum and the reconstruction with a myocutaneous flap.The patient doesn't show evidence of recurrent disease and the stability of her chest well preserved.Metastatic breast cancer to the sternum, if detected early and treated aggressively, …

SternumSettore MED/21 - Chirurgia ToracicaCytarabineBreast cancer Sternal metastasis SternectomyBone NeoplasmsBreast NeoplasmsAdenocarcinomaMiddle AgedCombined Modality TherapyMyocutaneous FlapSettore MED/18 - Chirurgia GeneraleFractures SpontaneousAntineoplastic Combined Chemotherapy ProtocolsHumansPleuraFemaleCyclophosphamideEpirubicin
researchProduct

Bleaching in vital teeth : combined treatment vs in-office treatment

2019

Background The aim of this study was to verify that there will be greater whitening in teeth treated with combined bleaching than in those that have been applied a clinical one and to evaluate the efficiency of the clinical treatment, those cases in which it is not able, or it is not wanted, to carry out the home phase. Material and Methods They were used 66 extracted anterior human teeth, which were divided into two study groups. On the one hand, the clinical group (ClG) consisted of 33 teeth, which were treated with a clinical guideline using 37.5% hydrogen peroxide in a single session of 4 applications of 8 minutes. On the other hand, the combinate group (CoG) consisted of 33 teeth, whic…

Study groupsbusiness.industryResearchDentistryEsthetic Dentistry030206 dentistry02 engineering and technology021001 nanoscience & nanotechnology:CIENCIAS MÉDICAS [UNESCO]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentchemistryUNESCO::CIENCIAS MÉDICASMedicineCombined therapyCarbamide peroxideHome treatment0210 nano-technologybusinessHydrogen peroxideGeneral DentistryClinical treatmentSingle session
researchProduct

Executive Function Domains among Children with ADHD: Do they Differ between Parents and Teachers Ratings?

2014

Abstract The purpose of this study was to evaluate parents and teachers behavior rating measures of executive functions (EFs) in everyday activities in ADHD children, predominantly inattentive (ADHD-PI) and combined type (ADHD-CT), relative to their typically developing peers. Sixteen children with ADHD combined type and fourteen with ADHD predominantly inattentive type were age- and gender-matched to thirteen typically developing peers. Both parents and teachers of the participants completed the BRIEF. As expected, the executive functioning of children with ADHD were rated significantly worse than those of controls by both parents and teachers. Thus, parent and teachers reported more EF im…

Teacher perceptionsInattentive typeEveryday activitieseducationNeuropsychologyinattentive typeExecutive functionsbehavioral disciplines and activitiesDevelopmental psychologyClinical PracticeTypically developingchildrenmental disordersADHDGeneral Materials SciencePsychologyADHD combined typeexecutive functioningClinical psychologyProcedia - Social and Behavioral Sciences
researchProduct

DECORIN EFFECTS ON PROTEOMIC PROFILING OF BREAST CANCER CELLS: AN UPDATED STUDY

2015

The malignant carcinomas are characterized by several capabilities acquired by the neoplastic cells, among which the ability to invade the extracellular matrix (ECM) and to establish a crosstalk with several ECM components. Under this respect, the extracellular microenvironment is an entity extraordinarily rich of information with opposite signals. Our group has long undertaken the study of the effects of ECM molecules on the behavior of cancer cells in vitro. Among the studied molecules, the decorin was found to exert a non-permissive effect on the growth and motility of the transfected tumor cells. The decorin, belongs to the family of small leucine-rich proteoglycans (SLRP) and is involv…

The malignant carcinomas are characterized by several capabilities acquired by the neoplastic cells among which the ability to invade the extracellular matrix (ECM) and to establish a crosstalk with several ECM components. Under this respect the extracellular microenvironment is an entity extraordinarily rich of information with opposite signals. Our group has long undertaken the study of the effects of ECM molecules on the behavior of cancer cells in vitro. Among the studied molecules the decorin was found to exert a non-permissive effect on the growth and motility of the transfected tumor cells. The decorin belongs to the family of small leucine-rich proteoglycans (SLRP) and is involved physiologically in the fibrillogenesis of collagen. In the last few year a new anti-oncogenic role has been proposed for decorin1. This study aimed to implement the knowledge on the effects of ectopic decorin on breast cancer cells using as a reference point the results already achieved by our research group2 on the experimental model format. By breast cancer cell line 8701-BC and its transfected clone DEC-C2. The extension of the proteomic analysis combined with the mass spectrometry allowed to triplicate the number of identified proteins in our model. Among the newly identified proteins were members of the classes of metabolic enzymes S100 family and cell motility proteins which revealed a net decrease in the decorin transfected cells. Of considerable importance is the observation that these classes of proteins are the most involved in metastatic progression. These results confirm and reinforce the anti-oncogenic role hypothesized for decorin. The work was co-funded by the Italian 5x1000 to COBS.DECORIN
researchProduct

Therapy response evaluation of malignant lymphoma in a multicenter study: comparison of manual and semiautomatic measurements in CT.

2014

Purpose: Comparison of manual one-/bi-dimensional measurements versus semi-automatically derived one-/bi-dimensional and volumetric measurements for therapy response evaluation of malignant lymphoma during CT follow-up examinations in a multicenter setting. Materials and Methods: MSCT data sets of patients with malignant lymphoma were evaluated before (baseline) and after two cycles of chemotherapy (follow-up) at radiological centers of five university hospitals. The long axis diameter (LAD), the short axis diameter (SAD) and the bi-dimensional WHO of 307 target lymph nodes were measured manually and semi-automatically using dedicated software. Lymph node volumetry was performed semi-automa…

ThoraxAdultMalemedicine.medical_specialtyRadiation DosageMalignant lymphomaYoung AdultAntineoplastic Combined Chemotherapy ProtocolsImage Interpretation Computer-AssistedMultidetector Computed TomographyMedicineHumansRadiology Nuclear Medicine and imagingLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryLymphoma Non-HodgkinMediastinumRetrospective cohort studyMiddle Agedmedicine.diseaseHodgkin DiseaseLymphomamedicine.anatomical_structureTherapy responseTreatment OutcomeMulticenter studyFemaleRadiologybusinessRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct